Hahn, CJ, Jagim, AR, Camic, CL, and Andre, MJ. Acute effects of a caffeine-containing supplement on anaerobic power and subjective measurements of fatigue in recreationally active men. J Strength Cond Res 32(4): 1029-1035, 2018-Studies show mixed results for the effects of caffeine on performance, warranting further investigation. The purpose of this study was to examine the acute effects of a caffeinecontaining supplement on anaerobic power and subjective measurements of fatigue during resisted sprinting on men. Fourteen recreationally active men (N = 14; [mean 6 SD], age: 21.0 6 0.7 years, height: 178.5 6 5.1 cm, body mass: 77.3 6 9.6 kg, and percent body fat: 12.6 6 4.8%) participated in a double-blind, placebo-controlled, within-subject crossover design study. The first visit required each participant to complete 3 sets of practice sprints on a nonmotorized treadmill ranging from 10 to 20 seconds. During the second visit, participants completed 5 more practice sprints ranging from 15 to 25 seconds. During the third and fourth visits, participants ingested one serving of a caffeine-containing or placebo beverage (the opposite beverage was consumed during the fourth visit), rested for 20 minutes, and completed a dynamic warm-up before sprinting. Anaerobic power was assessed using a countermovement vertical jump and nonmotorized treadmill sprint test. Psychological variables were scored using a 5-point Likert scale. No significant (p # 0.05) differences were observed between conditions for average (p = 0.22) or peak power (p = 0.43). Both conditions resulted in a significant increase in fatigue, although the increase was less for the caffeine condition (caffeine Δ = 0.93 and placebo Δ = 1.71). These findings indicated that the caffeinecontaining supplement improved perceived measures of fatigue but not power indices assessed through vertical jump or nonmotorized treadmill sprinting. The consumption of a caffeine beverage may be beneficial for reducing perceived fatigue during acute anaerobic exercise, particularly when repeated sprints are used.
INTRODUCTION

E
nergy drinks have been increasing in popularity, with purported benefits of increased mental and physical capabilities. Froiland et al. (12) reported energy drink usage to be as high as 72.9% among Division I college athletes. A variety of ingredients, including various vitamins, minerals, amino acids, and caffeine, are commonly found in energy drinks (4, 10, 22) . There are many studies examining the effects of caffeine-containing supplements on athletic performance (3, 6, 7, 11, 13, 15, 18, 20, 23, 29, 31, 32, 35) . The dosages of caffeine range from low to high and show mixed results as to each products effectiveness at increasing athletic performance (aerobic and anaerobic). With the number of energy drinks available to the public, however, research has not been able to address the safety and efficacy of each product nor their application as an ergogenic aid.
There are limited data regarding the acute effects of caffeine-containing supplement ingestion on anaerobic power (AP). Fukuda et al. (13) , however, examined the acute effects of consuming a pre-exercise supplement containing caffeine, creatine, and amino acids on anaerobic running performance. The authors (13) reported that anaerobic running capacity increased by 10.8% (p = 0.02) after ingestion of the supplement. Similarly, Anselme et al. (3) found increases (p , 0.02) in maximal AP during a cycle ergometer test after caffeine consumption (caffeine: 964 6 65.77 W and placebo: 903.7 6 52.62 W) and blood lactate after 5 minutes of recovery (caffeine: 10.23 6 0.97 mmol$L 21 and placebo: 8. 35 6 0.66 mmol$L 21 ).
In addition to the performance-related effects of caffeine, there has also been research investigating subjective measurements (SMs) such as markers of energy, fatigue, alertness, and focus during exercise. Childs (10) conducted a metaanalysis on energy drink consumption and their subsequent influence on mood and cognitive performance. It was concluded that there was a lack of empirical evidence between the interactions of caffeine and other energy drink ingredients on these psychological variables. There are several other caffeine-based preworkout supplementation studies that have shown positive improvements in alertness, energy, and focus as well as a decrease in fatigue both during and after bouts of high-intensity exercise (1, 9, 15, 23, 24, 28, 34) . For example, Alford et al. (1) found a significant improvement in choice reaction time (pretreatment: 529.5 6 19.9 ms, carbonated water: 521.7 6 12.8 ms, and Red Bull: 433.0 6 22.6 ms) between the caffeine-containing beverage, Red Bull, and a noncaffeinated control beverage. In addition, Hoffman et al.
(23) used a 5-point Likert scale and reported significantly higher subjective feelings of energy (3.5 6 0.5 vs. 3.1 6 0.5) and focus (3.8 6 0.5 vs. 3.3 6 0.7) after consumption of a caffeine-containing beverage compared with a noncaffeinated placebo, respectively.
Much of the current research regarding the ergogenic effects of caffeine or energy drink ingestion on exercise performance has examined dosages ranging from 5 to 13 mg$kg 21 body mass (31) . These levels are considered moderate to high dosages of caffeine and have been reported to cause several adverse side effects including: gastrointestinal discomfort, nervousness, mental confusion, headaches, inability to focus, and dizziness (16) . Research suggests that the undesirable side effects produced by moderate to high dosages of caffeine are not manifested when lower dosages (#3 mg$kg 21 body mass) of caffeine are ingested (16, 31) .
The lack of data on the potential ergogenic and cognitive effects of low dosages of caffeine ingestion in active individuals warrants further research. The consumption of low-dosage caffeine-containing beverages (i.e., soda, tea, and coffee) remains popular choices for consumers and should be studied to expand the knowledge base of both researchers and consumers. A lack of data evaluating the acute effects of caffeine on AP through a running-based anaerobic sprint test using a nonmotorized treadmill (NMT) also warrants further investigation because of limited data with this type of testing protocol. Therefore, the purpose of this study was to evaluate the acute effects of a commercially available, lowdosage, caffeine-containing supplement on AP, and SM of fatigue in recreationally active men.
METHODS
Experimental Approach to the Problem
This study used a double-blind, placebo-controlled, withinsubject crossover design. Participants reported to the laboratory for a total of 4 visits (separated by at least 48 hours) and were instructed (a) to abstain from exercise for 48 hours, (b) not to consume caffeine, alcohol, and tobacco products for 24 hours, and (c) not to eat for 3 hours before each visit. During the first visit, participants completed health, exercise history, and caffeine consumption questionnaires, gave written informed consent for participating, and went through an orientation session (practice sprints on the NMT) to mimic the experimental testing sessions (visits 3 and 4). For the second visit, body composition was assessed through air displacement plethysmography (Cosmed USA Inc., Concord, CA, USA), and another set of familiarization sprints on the NMT was completed, including 2 maximal sprints lasting 25 seconds against a load set at 18% of each individual participant's body mass.
When participants arrived for the experimental testing sessions (visits 3 and 4), they completed a baseline 5-point Likert scale questionnaire assessing feelings for energy, fatigue, alertness, and focus. Next, participants consumed either a commercially available caffeine-containing supplement or a placebo beverage (randomized by a third party) and remained seated for 20 minutes. After resting for 20 minutes, blood lactate was measured and a 5-minute dynamic warm-up was completed followed by a countermovement vertical jump (CMVJ) test. Participants then walked on a motorized treadmill for 5 minutes at a comfortable walking pace (2.5-3.5 mph). The same 5-point Likert scale questionnaire assessing energy, fatigue, alertness, and focus was completed again to assess changes from baseline to presprinting. Participants then completed a 25-second maximal effort sprint test against a load set at 18% of each individual's body mass.
Once the test was completed, participants immediately completed the 5-point Likert scale questionnaire a final time and underwent an active recovery of walking for 5 minutes at a comfortable walking pace (2.5-3.5 mph). Five minutes into the recovery, a second blood lactate level reading was obtained. The experimental testing sessions (visits 3 and 4) were similar in every aspect except for the beverage condition being consumed (this was randomized by a third party).
Subjects
Twenty college-aged men volunteered to participate in this study. After prescreening protocols, 3 were excluded from participating because of high caffeine consumption. Two participants were excluded from data analysis because of failure to capture power variables from the NMT, and one was excluded for discrepancies in dietary intake. Descriptive characteristics of the 14 participants who completed the study are presented in Table 1 .
Each participant was provided with a cover letter and informed consent form by the lead investigator. Those volunteering for the study were given the chance to ask questions before signing the informed consent. Inclusion criteria for this study entailed being a college-aged man who participated in at least 150 minutes of physical activity on a weekly basis, free from injury, and not a habitual caffeine consumer (i.e., an individual who consumed 8 ounces or more of caffeinated products daily or consumed multiple types of caffeine on 4 or more days in a week). Participant sex and age were self-reported. Approval for this study was given by the University of Wisconsin-La Crosse Institutional Review Board for Human Subjects.
Procedures
Body Composition. Air displacement plethysmography was used to obtain participant body composition (weight, fatfree, and fat mass). Participants were instructed not to eat, drink, or exercise at least 3 hours before being tested in the BOD POD. Participants removed eyeware, jewelry, and only wore a swim cap and compression shorts while in the BOD POD. Lung volumes were predicted. A wall scale and Broca plane were used to measure height (cm) of each participant. Weight measurement was used to identify the load (18% of body mass) in which participants would be sprinting against during the anaerobic sprint running test and to assess participant demographics. Supplement Protocol. The beverages for the experimental testing sessions were prepared and overseen by a third party in a double-blind fashion. The commercially available caffeine-containing supplement (Table 2) or placebo, zerocalorie liquid crystal light (Kraft Food Inc., Northfield, IL, USA), which was chosen for its similarity in color and taste, was administered in an opaque blender bottle with 8 ounces of cold water. An opaque bottle was used to mask the color of the beverage, although both the caffeine-containing supplement and the placebo were a similar shade of red. The beverage was then shaken and chilled in a refrigerator for 2 hours before participant consumption in the laboratory. Participants were instructed to consume the beverage within 5 minutes.
Performance Testing. Participants first completed a 5-minute dynamic warm-up consisting of body weight lunges, jumping jacks, body weight squats, broad jumps, and skips for height. After the dynamic warm-up, participants completed a CMVJ test using a jump mat (Just Jump System, West Warwick, RI). Participants were given 3 attempts with the highest value being recorded as their representative score. Jump height (in centimeter) and body mass (in kilogram) were later used to calculate lower body power (26) . The calculation used in the current study comes from a study by Johnson and Bahamonde (26) where reliability values of r = 0.88 for peak power and r = 0.82 for average power were reported.
A nonmotorized Force 2.0 treadmill (Woodway, Waukesha, WI) was used to assess anaerobic sprint performance. As shown previously, the anaerobic sprint running test has been shown to be a reliable method to assess AP characteristics (2, 27, 36) . Specifically, the current study used an anaerobic sprint running test developed by McLain et al. (27) , which found reliability for peak power and mean power to be high (r = 0.96-0.97 and coefficient of variation = 6-7%). Resistance was set at 18% of the participant's body mass, based on the results of the McLain et al. (27) study, which indicated that this value elicited the highest power output to be obtained without subjects experiencing adverse side effects (i.e., nausea, vomiting, light headedness, and dizziness). All participants were instructed to start the test in a crouched, split-stance, standing position to ensure that the waist tether was taut. The participants were then asked to sprint as fast as they could without pacing for the duration of the test. Pacer Performance Software (Innervations, Perth, Western Australia) was used to calculate the distance, velocity, power, work, and horizontal force generated by each of the participants. A speed sensor on the back of the treadmill was used to measure distance. The Pacer Performance Software was used to digitally filter the distance/time data and provides a velocity output as well as acceleration data, instantaneous velocity, horizontal force, and power. The waist tether worn by participants was connected to a load cell, which measured horizontal force (2).
Questionnaires. Subjective measurements of energy, fatigue, alertness, and focus were collected using a 5-point Likert scale, used previously to assess SM of fatigue (23) . A baseline score was recorded when participants entered the laboratory before beginning testing. Participants also completed the 5-point Likert scale before and immediately after sprinting on the treadmill. Subjects were asked to identify the number (1 = very low; 2 = low; 3 = average; 4 = high; and 5 = very high) that best correlated to how they felt at that moment regarding feelings of energy, fatigue, alertness, and focus.
Blood Lactate. Fingertip capillary blood samples were analyzed using the Lactate Plus Lactate Analyzer (Nova Biomedical Corporation, Waltham, MA, USA). Resting blood lactate was taken at baseline, before sprinting activities, and 5 minutes after the maximal effort sprint test. Blood lactate levels were used to assess the relative anaerobic component of the exercise trial and to examine whether the supplement altered this contribution.
Dietary Analysis. Participants completed a 2-day food log before each experimental testing session (visits 3 and 4) to confirm equal dietary patterns for each testing session (i.e., similar amounts of calories, carbohydrates, fats, and proteins), and that no caffeine and alcohol were consumed 24 hours before testing. Food log data were entered into the ESHA database (ESHA, Salem, OR, USA). The ESHA dietary analysis software categorized the food log information and was used to identify similarities and discrepancies in dietary intake before each testing condition.
Statistical Analyses
Data were analyzed using SPSS version 23.0 software (SPSS Inc., Chicago, IL, USA). Paired sample t-tests were used to analyze the differences between conditions (caffeine vs. placebo) for all APdependent variables and the food log data. Change from presprint to postsprint between conditions for lactate, energy, fatigue, alertness, and focus was compared using 2-way analyses of variance with repeated-measures and followup paired sample t-tests. An alpha level of p # 0.05 was considered to be statistically significant. 
RESULTS
Anaerobic power variables measured by the treadmill between conditions are presented in Table 3 .
There was no significant difference between the 2 conditions across all performance variables analyzed. A summary of variables measured by the CMVJ are presented in Table 4 .
Changes in SM throughout the testing protocol are presented in Table 5 . There was a significant time effect for subjective measures of energy with no differences between conditions. Ratings of fatigue were significantly increased from presprint to postsprint testing with greater levels during the placebo condition. No significant difference in blood lactate levels between conditions was observed (presprint p = 0.115 and postsprint p = 0.086). Presprint blood lactate levels were 1.6 6 0.5 mmol$L 21 for the caffeine supplement and 1.4 6 0.6 mmol$L 21 for the placebo condition. Postsprint blood lactate levels were 14.2 6 1.0 mmol$L 21 for the caffeine supplement and 13.5 6 1.3 mmol$L 21 for the placebo condition. Table 6 presents a summary of dietary intake before testing. There was a significant difference found in protein intake between the 2 conditions, with more protein consumed in the caffeine condition (Table 6 ).
DISCUSSION
The purpose of this study was to investigate the acute effects of a commercially available caffeine-containing supplement on AP measurements and SM of fatigue in recreationally active men. Results of the current study suggested that the caffeine-containing supplement had no impact on CMVJ or AP but positively influenced SM of energy and fatigue when compared with the placebo after a bout of high-intensity exercise. To our knowledge, this is the first study to examine this recently reformulated commercially available beverage and one of a few to evaluate a low-dosage caffeinecontaining supplement on AP and SM of fatigue.
Phosphocreatine and adenosine triphosphate production in the glycolytic pathway are the 2 main pathways for the production of anaerobic energy. When caffeine enters the body, it has been shown to influence activity at the neuromuscular and neurological levels. Specifically, research has shown caffeine to stimulate the central nervous system and delays fatigue by acting as an adenosine antagonist (4). Adenosine receptors are primarily located in type I muscle fibers (17) , which may explain the decreased likelihood of short-term high-intensity performance gains in anaerobic activities, such as sprinting, where type II muscle fibers are predominant (4) .
Previous studies have reported conflicting results on the influence of caffeine-containing supplements on AP. Data are equivocal because reports have indicated that caffeine diminishes (18, 30) , has no effect (5, 6, 8, 19) , or improves (3,7,11,32,35) short-term high-intensity activities. Although certain ingredient combinations may work synergistically to potentiate an ergogenic benefit, research seems to support that moderate (5-6 mg$kg 21 body mass) to high (7+ mg$kg 21 body mass) dosages of caffeine can increase AP (4). Eighteen resistance trained men were found to have higher peak power values (caffeine: 8.88 6 0.77 W$kg 21 body mass and placebo: 8.43 6 0.83 W$kg 21 body mass) measured by the Wingate anaerobic test after ingesting 5 mg$kg 21 of caffeine (35) . The significant increase in power could be due to the fact that participants consumed a moderate amount (5 mg$kg 21 body mass) of caffeine (29, 31) . The position stand on caffeine and performance from the International Society of Sports Nutrition states that caffeine is effective for enhancing sport performance in trained athletes when consumed in low-to-moderate dosages (;3-6 mg$kg 21 ) (14). The ergogenic effects of a low-dosage caffeine-containing supplement have not been well studied using a laboratorybased anaerobic sprint running test. The current study used a laboratory-based anaerobic sprint running test using an NMT. No differences were found between conditions for peak and average power (p = 0.43 and p = 0.22, respectively). These results are similar to those observed by Gwacham and Wagner (20) , who examined the acute effects of a caffeinecontaining supplement (120 mg) using a field-based AP test in Division I American Football players who completed six 35-meter sprints with 10 seconds of recovery between sprints. The authors also failed to observe a statistically significant increase in AP (p = 0.66) in subjects consuming a low caffeine dosage (120 mg) in a supplement.
Regardless of the dosage, it is largely unknown what the independent contribution of caffeine is regarding SM of fatigue (10) . The current accepted theory is that caffeine works as an adenosine antagonist and therefore delays fatigue, leading to increased reaction time, alertness, and mood (4,21). Alford et al. (1) found significant improvements in mental performance-including reaction time (Red Bull: 433.0 6 22.6 ms and carbonated water placebo: 521.7 6 12.8 ms) and alertness (Red Bull: 61.9 6 4.8 mm on a visual analog scale and carbonated water placebo: 36.5 6 2.2 mm on visual analog scale)-after consuming a Red Bull energy drink (80 mg of caffeine) and completing a 20-second anaerobic test on a cycle ergometer. The current study found that both conditions (caffeine vs. placebo) resulted in a significant decrease in energy levels with a concomitant increase in ratings of fatigue. In both instances, the changes were significantly larger in the placebo condition.
One explanation to the lack of a performance benefit after caffeine ingestion in the current study could be the relatively low caffeine dose (120 mg). Most of the participants in this study reported feeling like they had consumed the caffeinated beverage, but that it did not make them feel as though they were more alert and focused. This could be due to the fact that participants received an absolute amount of caffeine rather than a relative amount based on body mass. In regard to energy drink consumption, it is more typical to receive an absolute volume than a relative volume because this is how most caffeinated dietary supplements are manufactured and consumed (20) .
Previous research has suggested that caffeine dosages ranging from 2 to 9 mg$kg 21 of body mass may be needed for an ergogenic effect, but that a dosage of 5-6 mg$kg 21 of caffeine seems to have the greatest benefit (4,7,29,31), particularly for muscular endurance and AP-related activities. A relative amount of caffeine in a typical energy drink generally ranges from 1 to 2 mg$kg 21 of body mass (4) . The absolute amount of caffeine the participants received in the current study was 120 mg, which translates to a relative dose of 1.5 mg$kg 21 and therefore was lower than dosages that have produced an ergogenic effect. In a study by Van Nieuwenhoven et al. (33) , runners who consumed 1.3 mg$kg 21 of a caffeine-containing supplement had no increase in endurance performance. Jagim et al. (25) found an increase in mean power (preworkout: 1,468 6 304 W and placebo: 1,397 6 257 W) as measured by an anaerobic sprint test after consumption of a multiingredient preworkout supplement that contained 300 mg of caffeine.
It is possible, however, that dietary intake could have been a confounding variable. Specifically, each participant was instructed to record their dietary intake in a food log 2 days before their testing session and to follow normal dietary patterns. There was a significant difference found in protein consumption between the 2 conditions (caffeine: 134.14 6 48.70 g and placebo: 116.00 6 36.35 g). However, this was an acute study where the main purpose of the food log was for participants to have a place to record and see how they were eating before testing. Ideally, future studies should control for dietary intake by providing standardized meals.
PRACTICAL APPLICATIONS
In conclusion, the findings of this study indicated that an acute dose of the caffeine-containing supplement was statistically superior for reducing perceived fatigue, but not CMVJ or AP assessed on an NMT. Therefore, it may be appropriate to consume the current caffeine-containing supplement for reduced feelings of fatigue during anaerobic activities, particularly where repeat sprint bouts may be required.
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